Achieve Life Sciences to present 52-week cytisinicline efficacy data from ORCA-OL smoking, e-cigarette cessation trial at CHEST 2026
Bitget2026/09/28 12:31- Achieve Life Sciences flagged new 52-week trial data on cytisinicline for smoking and e-cigarette cessation for presentation at CHEST 2026.
- Results from the open-label ORCA-OL study are scheduled for Oct. 20, 2026, indicating sustained abstinence during year-long treatment.
- The trial enrolled 475 adults who previously participated in earlier cytisinicline studies and continued to smoke or vape daily.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
